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ABSTRACT 
 
Cancer progression is dependent, in part, on interactions between tumor cells and the host 
microenvironment. During pregnancy, physiological changes occur that include inflammation 
and reduced immunity, both of which can promote tumor growth. Accordingly, tumors are 
observed to be more aggressive and to have greater proclivity toward metastasis during 
pregnancy. In this work, myeloid-derived suppressor cells (MDSC), a population of 
heterogeneous and pluripotent cells that can down-regulate immune responses during 
pathological conditions, were studied in the context of mouse and human gestation. The gene 
expression profile of mouse MDSC has been shown to differ in pregnant and virgin mice, and 
the profile in pregnant animals bears similarity to that of MDSC associated with the tumor 
microenvironment. Common induced genes include Fibronectin1 and Olfactomedin4, which are 
known to be involved in extracellular matrix remodeling and tissue permissiveness to tumor cells 
implantation. Our observations suggest that mouse MDSC may represent a shared regulatory 
mechanism of tissue permissiveness that occurs during the physiological state of gestation and 
tumor growth. 
Pregnancy-associated changes in immunosuppressive myeloid cell activity have also been studied 
in humans. We show that CD33+ myeloid cells isolated from PBMC (peripheral blood 
mononuclear cells) of pregnant women are more strongly immunosuppressive on T cells than 
CD33+ cells removed from non-pregnant subjects. During murine gestation, decreased natural 
killer (NK) cell activity is responsible, at least in part, for the increase in experimental metastasis. 
However, although peripheral blood NK cell numbers and cytotoxicity were slightly reduced in 
pregnant women, neither appeared to be regulated by CD33+ cells. Nevertheless, based on its 
observed suppression of T cell responses, the CD33+ PBMC subset appears to be an appropriate 
myeloid cell population to study in order to elucidate mechanisms of immune regulation that 
occur during human pregnancy. Our findings regarding the immunosuppressive function of 
CD33+cells and the role of NK cells during human pregnancy are consistent with the notion that 
changes in the function of the immune system participate in the constitution of a permissive soil 
for tumour progression. 
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INTRODUCTION 
1. Tumor-host interactions 
Metastasis is a multistage process that constitutes the primary cause of cancer related death. It 
requires tumor cells to detach from the primary tumor mass, migrate toward and eventually  
invade lymphatic or blood vessels, survive within the circulation, attach to the endothelium of 
distant organs, penetrate the endothelial barrier and establish new tumor colonies. The process is 
highly inefficient since less than 0.1% of tumor cells that penetrate the circulation will eventually 
generate metastatic colonies (1)(2). 
Throughout this process, interactions occur between cancer cells and the host 
microenvironment, including the immune system. It is well established that interactions between 
tumor cells and the host tissue stroma play a key role in determining whether and how any given 
solid malignancy will develop. In most cases, tumor cells take control of stromal cell functions 
for their own benefit and dictate the rules of engagement to the host tissue microenvironment. 
The host immune system also participates in tumor growth regulation through the recognition 
and destruction of cancer cells. However, cancer cells display properties that help them avoid 
immunosurveillance, including selection of tumor-cell variants and subversion of the immune 
system (3).  
Observations of this cross-talk between tumor cells and the host microenvironment that may 
seem to “prepare” a tissue for subsequent invasion and secondary growth, have led to the 
concept of “pre-metastatic niches”. Distal host tissues thus appear to adopt functional features 
that facilitate tumor cell implantation, survival and division. An important question to address is 
whether these niches are exclusively tumor-associated or whether they reflect a more general 
response of the organism to a variety of potentially pathological or physiological stimuli, as may 
occur during pregnancy.  
2. Metastasis during pregnancy 
Cancers that develop during pregnancy usually have a worse prognosis than those that arise in 
non-pregnant women of a comparable age. One of the best documented example is breast 
cancer. Women who develop breast cancer during pregnancy (or within one year of giving birth) 
have tumors that are often very aggressive with high metastatic proclivity (4)(5). Although 
increased hormone production may contribute to tumor progression, 80% of breast cancers in 
this age group are hormone receptor negative, suggesting that mechanisms other than hormone 
exposure are required to promote cancer aggressiveness. These include potential changes in the 
immune system that occur during gestation or the peripartum. 
Two of the most important changes during pregnancy are reduced immunity, to allow proper 
fetal implantation, and induction of inflammation. These physiological changes may help install 
permissive niches for tumor growth. However, little is known about the host factors during 
pregnancy that determine whether or not a disseminating tumor cell will be able to spawn a new 
colony once it reaches its metastatic site.  
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3. Immunity & pregnancy 
During normal pregnancy, various immunological changes are observed. Humoral (antibody-
mediated) immunity of the mother is required to protect her and her fetus from the environment 
while the fetus develops its own immune system, imposing adaptation on the mother to 
accommodate its presence (6). The human placenta contains a high number of immune cells, 
such as macrophages, regulatory T-cells and dendritic cells. NK cells constitute a markedly 
predominant population and T lymphocytes are particularly abundant. Many diverse modulators 
such as sex-hormones, maternal antibodies, the complement system and cytokines are also 
recruited to the placental interface (6).  
Modifications of the immune system that are involved in preventing rejection of the fetus include 
absence of classical class I MHC molecules on the surface of fetal cells, hyporesponsiveness of 
immune cells as a result of Indoleamine 2,3-dioxygenase (IDO) activity, silencing of alloreactive 
T-cells by regulatory T-cells and expression of NK and T-cell modulating HLA-G molecules (1).  
In addition to immunological changes, pregnancy is associated with an inflammatory response 
that varies according to the trimester. Inflammation is required for fetal implantation during the 
first trimester, becomes slightly reduced during the second trimester which is a quiescent fetal 
growth period and increases during the final trimester to prepare delivery (7)(6). 
Local changes are supported by systemic changes during pregnancy. Thus, reduction in T-cell 
and B-cell numbers and activity are detectable in maternal blood. In addition, NK cells appear to 
be particularly important in early pregnancy, but after 20 weeks of gestation, their numbers 
decrease in maternal blood and display reduced activity. The decrease in T-cell, B-cell and NK 
cell functions and numbers is accompanied by an increase in innate immunity, which may offset 
their downregulation. An increase in the number of phagocytic immune cells, including 
monocytes, dendritic cells and neutrophils, is observed in maternal blood from as early as 
gestational week 20 all the way to week 36 (8). 
A population of myeloid cells called myeloid derived suppressor cells (MDSC) is suspected to 
play a critical role in modulating the immune system in situations as distinct as tumor growth and 
pregnancy.  
4. MDSC and their potential role in pregnancy 
MDSC are a population of heterogeneous, immature and pluripotent myeloid cells that are 
precursors of granulocytes, macrophages and dendritic cells (9). They were recently shown to 
accumulate in mice in various pathological conditions, including cancer, infection and 
autoimmune diseases, where differentiation of immature myeloid progenitor cells is partially 
blocked. These immature myeloid cells are able to down-regulate immune responses and thereby 
facilitate tumor progression (10)(11).  
MDSC are induced and/or activated by multiple proinflammatory mediators produced by tumor 
or host cells in the tumor microenvironment (Figure 1) (10)(11). Once activated, their production 
of immune suppressive factors, such as Arginase 1, inducible Nitric Oxide Synthase (iNOS), 
reactive oxygen species (ROS) and nitric oxide (NO) is increased, thereby inhibiting T cell and 
NK cell functions (10)(11). 
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These immature progenitor cells express receptors that allow their identification in various 
tissues. In mice, MDSC are characterized as CD11b+Gr-1+ cells (12). Under pathological 
conditions, MDSC found in blood and tissues outside the bone marrow display a granulocytic 
(80-90%) or monocytic phenotype (10-20%) with different surface markers. The Gr-1 marker is 
common to the two subsets and is also known as the Ly-6G/Ly-6C epitope. The equivalent 
population of cells is much more complex to define in humans, where their features appear to 
vary according to the tissue microenvironment or their differentiation state. Human peripheral 
blood MDSC have been characterized by expression of CD11b, CD15, CD33, CD66b, CD124 
and low expression levels of HLA-DR (11)(13).  
 
MDSC accumulate in the context of tumor growth, inflammation and the physiological condition 
of pregnancy. Observations made in the laboratory have shown that tumor-bearing pregnant 
mice develop metastasis more aggressively than virgin counterparts (14)(1)(4). Remarkably, this 
was shown to be the case irrespective of tumor type or model. In-depth investigation of the 
putative mechanisms involved revealed that pregnancy induces accumulation of MDSC that 
infiltrate a broad range of tissues, to help generate a permissive soil for tumor cell engraftment. 
These MDSC effectively block T and NK cell activity and were shown to be responsible for 
accelerated and diffuse metastatic tumor growth in pregnant mice (15)(1)(4). 
    
Figure 1: MDSC are induced and/or activated by multiple proinflammatory mediators. MDSC 
accumulate in the blood, bone marrow, lymph nodes, and at tumor sites in response to pro inflammatory 
molecules produced by tumor cells or by host cells in the tumor microenvironment. These factors 
include PGE2, IL-1β, IL-6, VEGF, S100A8/A9 proteins, and the complement component C5a. 
                      
 
7 
 
SPECIFIC AIMS OF THE STUDY 
   
Since we know that pregnancy-associated changes promote tumor progression in mice, at least in 
part due to the contribution of MDSC, our specific aims are the following:  
1. To evaluate whether the gene expression profile of MDSCs during pregnancy differs 
from that in non-pregnant (or virgin) animals, with the goal of elucidating how this 
MDSC population augments its immunosuppressive properties and why it accumulates 
during the physiological state of gestation. This may allow development of tools to 
neutralize their function and to reverse their phenotype in order to restore a competent 
immune response. 
 
2. To determine whether the functions of MDSC are different in human blood cell isolates 
obtained from pregnant and non-pregnant women. We will try to transpose the 
knowledge obtained from mouse models to human pregnancy and assess whether MDSC 
accumulate more and are functionally more efficient than in non-pregnant women.  
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RESULTS & DISCUSSION 
1. Gene expression profiles of MDSC extracted from pregnant mice display 
features that may augment permissiveness for tumor progression 
1.1. Results 
1.1.1. Enrichment of  MDSCs 
To assess the expression profile of MDSC during pregnancy, a protocol to isolate and enrich this 
population had to be optimized. Eight 16-day-pregnant C57BL/6 mice (equivalent to 30th weeks 
of human pregnancy) and six non-pregnant C57BL/6 mice were euthanized and splenocytes 
isolated. After MACS-sorting of the Gr1High-Ly-6G positive cells on two columns, the enrichment 
of the cell suspension was assessed by flow cytometry using anti-Gr1, anti-CD11b and anti-CD45 
antibodies. The percentages of CD45+ CD11b+ and Gr1High populations were doubled from the 
initial splenocyte populations (Figure 2: 28% and 37% MDSC before sorting, to 75% and 79% 
after the enrichment for virgin and pregnant mice, respectively).  
 
 
Figure 2: Representative data of flow cytometry analysis of splenocyte fractions isolated from pregnant 
and virgin mice, before and after Gr1High-Ly-6G positive cell sorting. These results were gated on the 
leukocyte CD45+ cell population. Cells were fluorescently stained with anti-CD45-FITC, anti-CD11b-PE 
and, anti-Gr1-APC. 
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1.1.2. Hybridization on Affymetrix microarrays 
After MDSC isolation and extraction of their total RNA (Qiagen RNeasy® Mini Kit), 
microarrays were performed at the Genomics Technology Facility of Lausanne (GTF). Four 
RNA samples extracted from MDSC of pregnant (2) and virgin mice (2) were initially prepared 
and transferred to the GTF. Because RNA quality had to be optimized, only one of each RNA 
extractions (1P and 1V) was used in the initial experiment for hybridization to an Affymetrix 
Mouse Gene 1.OST array. 
A second experiment was done with 2 batches of MDSC extracted from pregnant (2) and virgin 
(2) mice. After analysis of the whole dataset (6 samples), a list of 81 relevant probes appeared to 
be differentially expressed (69 up- and 12 down-regulated – Table 1) by cells extracted from 
pregnant mice compared to those from virgin mice. The probes were sorted according to 
log2FC. Among these genes, several are known to be involved in facilitating tumor progression 
or linked to poor prognosis in cancer, including Fbn1 (16) (17), Prg4 (18), Abca13 (19), Itgb2l 
(20), Cldn1 (21), Fcnb (22), Olfm4 (23), or Saa3 (24). Some of these genes were also linked to 
inflammation, including chitinases, Lbp (25), or Rgs1 (26). 
 
Gene symbol Gene description log2FC 
Up-regulated genes   
Fn1 fibronectin 1 2.058 
Prg4 proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein) 1.90441 
Lipg lipase, endothelial 1.87258 
Inhba inhibin beta-A 1.72573 
Olfml2b olfactomedin-like 2B 1.68228 
Abca13 ATP-binding cassette, sub-family A (ABC1), member 13 1.64987 
Itgb2l integrin beta 2-like 1.60919 
4930438A08Rik RIKEN cDNA 4930438A08 gene 1.59185 
Cldn1 claudin 1 1.55661 
Chi3l7 chitinase 3-like 7 1.55356 
Lbp lipopolysaccharide binding protein 1.52177 
Fcnb ficolin B 1.43574 
Olfm4 olfactomedin 4 1.43459 
Saa3 serum amyloid A 3 1.42808 
Ica1 islet cell autoantigen 1 1.42732 
Chi3l3 chitinase 3-like 3 1.41066 
Syne1 synaptic nuclear envelope 1 1.32292 
Serpinb10-ps serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10 
 
1.31097 
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 1.29145 
Thbs1 thrombospondin 1 1.28941 
Cd177 CD177 antigen 1.2728 
                      
 
10 
 
Crispld2 cysteine-rich secretory protein LCCL domain containing 2 1.25273 
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 1.25165 
Gypa glycophorin A 1.21583 
Ankrd22 ankyrin repeat domain 22 1.2136 
Orm1 orosomucoid 1 1.20731 
Mki67 antigen identified by monoclonal antibody Ki 67 1.20162 
Kif11 kinesin family member 11 1.1933 
Slc4a1 solute carrier family 4 (anion exchanger), member 1 1.19264 
Syne1 synaptic nuclear envelope 1 1.17749 
Pde7b phosphodiesterase 7B 1.17694 
Arg1 arginase, liver 1.16789 
Gca Grancalcin 1.15974 
Alox15 arachidonate 15-lipoxygenase 1.15291 
Ncam1 neural cell adhesion molecule 1 1.14901 
Bub1 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) 1.14137 
Lta4h leukotriene A4 hydrolase 1.13636 
Ccna2 cyclin A2 1.11758 
Prc1 protein regulator of cytokinesis 1 1.09922 
1100001G20Rik RIKEN cDNA 1100001G20 gene 1.09714 
Aspm asp (abnormal spindle)-like, microcephaly associated (Drosophila) 1.0954 
Acpl2 acid phosphatase-like 2 1.0902 
Camp cathelicidin antimicrobial peptide 1.08793 
Adpgk ADP-dependent glucokinase 1.08539 
Slco4c1 solute carrier organic anion transporter family, member 4C1 1.07311 
Rhou ras homolog gene family, member U 1.0719 
Prr11 proline rich 11 1.0688 
Depdc1a DEP domain containing 1a 1.06875 
Ly6g5b lymphocyte antigen 6 complex, locus G5B 1.06418 
Cpne2 copine II 1.06135 
Cebpe CCAAT/enhancer binding protein (C/EBP), epsilon 1.06022 
Cxcr1 chemokine (C-X-C motif) receptor 1 1.05865 
Kif18b kinesin family member 18B 1.05534 
Plk1 polo-like kinase 1 (Drosophila) 1.04735 
Gpr97 G protein-coupled receptor 97 1.04475 
Dach1 dachshund 1 (Drosophila) 1.04457 
Plscr1 phospholipid scramblase 1 1.04081 
Pf4 platelet factor 4 1.03449 
Aff2 AF4/FMR2 family, member 2 1.03064 
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Nt5e 5' nucleotidase, ecto 1.03045 
Rnf125 ring finger protein 125 1.02841 
Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 1.02762 
Aldh3b2 aldehyde dehydrogenase 3 family, member B2 1.02673 
1700055N04Rik RIKEN cDNA 1700055N04 gene 1.02239 
Trp53inp2 transformation related protein 53 inducible nuclear protein 2 1.0212 
Depdc1a DEP domain containing 1a 1.0118 
Anln anillin, actin binding protein 1.01177 
Tinagl1 tubulointerstitial nephritis antigen-like 1 1.01132 
2310005G13Rik RIKEN cDNA 2310005G13 gene 1.00302 
Down-regulated genes   
Rgs1 regulator of G-protein signaling 1 -2.02762 
Apol7c apolipoprotein L 7c -1.57539 
Ccl24 chemokine (C-C motif) ligand 24 -1.19042 
Slamf8 SLAM family member 8 -1.17702 
Tsen15 tRNA splicing endonuclease 15 homolog (S. cerevisiae) -1.10621 
Rgs13 regulator of G-protein signaling 13 -1.08822 
Zdhhc2 zinc finger, DHHC domain containing 2 -1.08753 
Dip2c DIP2 disco-interacting protein 2 homolog C (Drosophila) -1.08659 
Il1a interleukin 1 alpha -1.08264 
Bcl2a1c B-cell leukemia/lymphoma 2 related protein A1c -1.05915 
Iigp1 interferon inducible GTPase 1 -1.02036 
Tnfsf18 tumor necrosis factor (ligand) superfamily, member 18 -1.00411 
 
Table 1: Differentially expressed genes between MDSC extracted from pregnant and virgin mice. In red, 
are 5 genes selected for qRT-PCR validation of the microarray data. 
 
1.1.3. Validation of microarray results by qReal-Time RT-PCR 
Among genes up-regulated in MDSC extracted from pregnant mice, five of them (in red in the 
table 1) were chosen for qReal-Time RT-PCR validation, with a log2FC ≥ 1.41 (= at least 2 fold 
more expressed). MDSC were extracted from 3 new virgin and 4 16-day pregnant C57BL/6 
mice, and mRNA was prepared for analysis by qRT-PCR (Figure 3). The 5 selected genes are 
involved in matrix remodeling, tumor progression and regulation of innate immunity. Four of 
them appeared to be significantly overexpressed (p<0.05 or p<0.01), confirming the initial 
hybridization data. 
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Figure 3: qReal-Time RT-PCR validation of selected up-regulated genes identified by microarray analysis. 
 
1.1.4. Comparison of MDSC genes expressed in pregnant and 
tumor-bearing mice 
To validate the involvement of these genes in tumor development, four healthy and four tumor-
bearing mice (TBM) were used for splenocyte extraction, MDSC sorting and qRT-PCR 
assessment of the expression of the five selected genes. The same expression profile observed in 
the comparison between pregnant and virgin mice was observed when MDSC derived from 
TBM were compared to their healthy animal counterparts (Figure 4), consistent with the 
functional implication of these genes in tumor growth. 
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Figure 4: qReal-Time RT-PCR of genes expressed by MDSC extracted from TBM compared to healthy 
mice. 
 
The mannose receptor, metalloprotease 9 (MMP9), interleukin-1β (IL-1β) and tumor necrosis 
factor-α (TNFα) mRNA were also shown to be increased in MDSC extracted from pregnant 
mice compared to virgin ones, as well as from TBM as expected (Figure 5). Indeed, these four 
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genes that encode a receptor, a protease and two cytokines, are known to facilitate tumor 
progression through their overexpression in tumor-associated macrophages (TAM). 
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Figure 5: qReal-Time RT-PCR of genes expressed by MDSC extracted from pregnant and TBM 
compared to virgin-healthy mice. 
 
1.2. Discussion 
As described, gene expression profiling was assessed in two separate experiments using 2 
different RNA extractions. In these gene expression profile studies aimed at further 
characterizing pregnancy-associated MDSC, the arrays showed different patterns of expression: 
no change, slight or important increase or decrease in gene expression. First, we observed that 
the transcriptome of pregnancy-associated MDSC was significantly different from that of MDSC 
in virgin mouse tissues. The second observation was the similarity between the gene expression 
profiles of MDSC from pregnant and tumor-bearing mice. 
Herein, we focused our study on MDSC genes that were overexpressed in both pregnant 
compared to virgin and tumor burdened compared to tumor-free mice. However, we cannot rule 
out that many genes that are marginally upregulated in pregnant mouse MDSC are also 
functionally important in the tumor microenvironment. Silencing of several genes expressed in 
MDSC may also be important during pregnancy but these genes were not assessed at this stage in 
this work.  
The selected differentially expressed genes in MDSC isolated from virgin versus pregnant mice 
have various functions. A summary of some of their functions is provided below.  
Olfactomedin-4 (OLFM4) gene encodes the antiapoptotic protein GW112 or the G-CSF-
stimulated clone 1 protein. The OLFM4 protein is expressed during normal myeloid-specific 
lineage differentiation (27). The suspected role of OLFM4 in tumorigenesis is mainly related to 
its ability to regulate apoptosis, cell cycle (cell proliferation by promoting the S-phase transition) 
and cell adhesion (through interactions with lectins and cadherin)(28). Perturbations in OLFM4 
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expression decrease cell adhesion and alter cell-to-extracellular matrix interactions, with the 
possible consequence of cellular transformation and metastasis (27). Furthermore, OLFM4 
protein has been shown to be highly expressed in several types of tumors, especially in 
gastrointestinal cancers (25) and gastric H. pylori infection where it downregulates T cell immunity 
and leads to chronic inflammation. OLFM4 is therefore an excellent candidate molecule to 
provide an explanation for some of the functions observed in pregnancy-associated MDSC.  
Ficolin B (FCN2) also known as Fcn2, ficolin-2, ficolin-beta, collagen/fibrinogen domain 
containing lectin. This gene product has carbohydrate binding and opsonic activity for apoptotic/ 
necrotic cells. The mouse ficolin B corresponds to human M-ficolin, a leukocyte-associated form 
of ficolins (29). Mouse ficolin B is mainly expressed in the bone marrow and spleen, as well as by 
peritoneal macrophages, whereas M-ficolin has been localized to the surface of monocytes and 
identified in the secretory granules of neutrophils and monocytes (30). Human ficolin activates 
the lectin branch of the complement cascade when they bind to microbial targets. It also activates 
endothelial cells. In contrast, mouse ficolin B does not activate complement. Functions of this 
protein have still to be understood, in addition to its involvement in innate immunity. 
Inhibin beta-A (INHBA) also known as activin beta-A chain, follicle-stimulating hormone-
releasing protein. Activins and inhibins are cytokines involved in cell differentiation and 
proliferation. Activins, which belong to the TGF-β superfamily, are homo- and heterodimers 
composed of inhibin/activin betaA-subunit or betaB-subunit, whereas inhibins are heterodimers 
of an alpha- and one of the beta-subunits (31). In humans, the beta-A subunit gene expression 
has been shown to be higher in both local and metastatic breast carcinoma than in normal tissue. 
But the effects and mechanisms of action of inhibin on cancer cells are largely unknown (32). IL-
1β is known to stimulate activin A and INHBA mRNA expression and is also an activator of 
MDSC. 
In addition to its growth/differentiation factor function, INHBA acts as a hormone that 
negatively regulates pituitary FSH secretion. Serum levels of inhibin have been shown to be 
associated to the size of granulosa-cell tumors and can therefore be used as a marker for primary 
as well as recurrent disease of the ovary (33).  
Fibronectin 1 (FN1) also known as migration-stimulating factor (MSF), an oncofetal isoform of 
Fibronectin. It is a glycoprotein present in soluble dimeric form in plasma, and in a dimeric or 
multimeric form at the cell surface and in the extracellular matrix (ECM). Fibronectin 1 is 
involved in cell adhesion and migration in processes that include embryogenesis, wound healing, 
blood coagulation, host defense, and metastasis. 
The continuous and dysregulated remodeling of the ECM in tumors leads to the aberrant 
presence of numerous extracellular matrix components that are not usually found in normal 
tissues (34). In transformed cells and in tumors, the splicing pattern of Fibronectin pre-mRNA 
becomes altered, leading to an increased expression of oncofoetal isoforms, including MSF. 
MSF is a truncated fibronectin with motogenic activity, relevant to cancer development. In 
addition to stimulating cell migration, FN1 enhances hyaluronan synthesis, proteolytic activity, 
angiogenesis and the preparation of premetastatic niches. Thus MSF contributes to the motile 
phenotype of neoplasic cells (34) and has a strong chemotactic activity for monocytes and tumor 
cells. MSF is produced by various cell types, including neoplastic cells, tumor-associated vascular 
endothelial cells and type M2-macrophages and TAM (34). In the present study, we have shown 
that MDSC from pregnant mice produce increased amounts of MSF.  
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Chitinase 3-like 3 (Chi3l3) is also known as secreted protein Ym1 and eosinophil chemotactic 
cytokine. In mammals, although endogenous chitin or chitin synthases do not exist, chitinase and 
chitinase-like proteins(CLP) are endogenously expressed and dysregulated in allergic disorders 
and a variety of diseases characterized by chronic inflammation and tissue remodeling. CLP lack 
chitinase activity and their roles have still to be investigated. Chi3l3 is rodent-specific CLP and is 
expressed in macrophages after stimulation with IL-4 or IL-13 in response to parasitic infection 
or allergic stimulation, and is induced by Th2 cytokines. Chi3l3 is also expressed in dendritic cells 
and mast cells. The protein is known to be chemotactic for eosinophils, T lymphocytes, and 
polymorphonuclear leukocytes (35). Even if Chi3l3 is only expressed in mice, the CLP family 
contains human members, which are known to be involved in a variety of inflammatory, 
remodeling, and neoplastic disorders (35). 
The difference in Chitinase 3-like 3 gene expression between pregnant and virgin mice was not 
significant. One potential explanation is the large scattering of Chi3l3 expression values among 
pregnant mice MDSC and the small number of samples. The mean of the gene expression level is 
affected by these extreme values. Another limiting factor of these experiments lies in the step of 
MDSC purification and the risk that genes found to be overexpressed in pregnant mouse MDSC 
are not exclusively coming from this cell population. Although RNA was prepared following cell 
purification some residual cells unrelated to MDSC may still persist. 
The functions in the tumor context of these selected overexpressed genes are largely unknown. 
However they appear to be promising candidates to help understand the role of MDSCs in 
pregnancy and tumorigenesis. OLFM4 and MSF seem to be particularly interesting in the context 
of tissue permissiveness, and further investigation that involve the use of knockout and other 
transgenic mouse models, should be performed in the future. Our experiments also suggest a role 
of the immune population of MDSC in ECM remodeling and cell adhesion, both of which play 
important roles in tumor progression.  
A larger study comparing MDSC content from tumor-bearing and tumor-free animals was also 
performed as described above. The same upregulation of the selected genes was observed, 
confirming the involvement of MDSC in facilitating metastasis during pregnancy. 
The final goal of this study is to provide clues as to how MDSC facilitate tumor growth and how 
pregnancy might provide a favorable immunological precursor state for tumor implantation. 
Interestingly, additional data have revealed similarities between pregnant mouse MDSC gene 
expression and TAM. Macrophages undergo activation in response to environmental signals that 
lead to polarization into at least two subtypes: proinflammatory M1 macrophages and protumor 
M2 macrophages. Tumors have their own associated-macrophages, which undergo a wide 
spectrum of polarized activation states, and have the potential both to elicit tumor and tissue 
destructive reactions and to promote tumor progression (macrophage balance). In general, TAM 
from established tumors have properties of activated M2 cells, but not only so, and as such 
support cancer progression and metastasis. Therefore, TAMs are a key component of pathways 
connecting inflammation and cancer (36)(37)(38). 
MDSC share several similarities with TAM, as both cell types secrete elevated levels of IL-10, are 
able to inhibit the T-cell response, and promote angiogenesis. Furthermore, and in distinction 
from TAM, a relevant immunosuppressive mechanism of MDSC is mediated by the concomitant 
expression of the inducible forms of both nitric oxide synthase and arginase, which are 
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considered to be hallmarks of M1 and M2 macrophages, respectively, highlighting the plasticity 
of these cells (36)(37)(38). 
Two examples of common induced genes observed during this study, expressed by pregnant and 
tumor-bearing mouse MDSC, are the mannose receptor gene (or CD206) and MMP9, usually 
prominent markers of the M2-macrophage phenotype. Moreover, both types of MDSC 
overexpressed IL-1β and TNFα, as do M1 proinflammatory macrophages, suggesting the 
plasticity described above: pregnancy may prepare MDSC to differentiate both into inflammatory 
macrophages and into TAM, even in the absence of tumor cells, consistent with the potential role 
of these cells to create a permissive microenvironment already under physiological conditions. 
 
2. MDSC functions during human pregnancy 
2.1. Results 
2.1.1. Choice of the MDSC population 
In mouse models, MDSC accumulate in organs and blood, and have more potent 
immunosuppressive activity in pregnant than in virgin mice. To address the possible variations of 
MDSC in human pregnancy and in tumor growth facilitation related to pregnancy, we applied all 
of the above techniques to isolating human MDSC. The first step was to identify a candidate 
myeloid cell subtype. Unlike the MDSC population in mice that is well characterized, the 
phenotype of human heterogeneous MDSC populations is still unclear. Human MDSC are often 
described as CD14+, CD33+, CD11b+, HLA-DRlow for the monocytic subset and CD15+, CD33+, 
CD11b+, HLA-DR-, CD66b+ for the granulocytic subset. Several pilot studies were required to 
optimalize the identification of the MDSC in humans. We collected blood samples from final 
trimester pregnant women and isolated the peripheral blood mononuclear cell (PBMC) and the 
granulocyte layers by Lymphoprep (see materials and methods) in order to isolate the two 
subpopulations (monocytic and granulocytic) of MDSC.   
We then extracted and sorted the CD11b+ and CD33+ cells in these two layers, as well as T and 
NK cells. We tested the immunosuppressive effects of CD11b+ and CD33+ cells on sorted T and 
NK cells (co-cultures followed by a T cell proliferation assay or by a NK cell cytotoxicity assay). 
Based upon the known literature (39) and on our preliminary results on different blood samples 
(Figure 6 and Figure 7), we identified the PBMC layer and selected CD33+ myeloid cells for 
pregnant versus non-pregnant comparison.  
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Figure 6: 3H-Thymidine T cell proliferation assay confirmed the immunosuppressive effect of the CD33+ 
PBMC co-cultured with T cells, whereas CD11b+ PBMC and CD33+/CD11b+ Granulocytes have no 
effect on T cell proliferation. Cells extracted from the blood of a non-pregnant woman. Proliferating T 
cells incorporate 3H-Thymidine. 
 
 
 
 
Figure 7: 3H-Thymidine T cell proliferation assay. Validation of the immunosuppressive effect of the 
CD33+ PBMC compared to the CD11b+ PBMC population. Cells extracted from the blood of a non-
pregnant woman. 
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2.1.2. Immunosuppressive effect of CD33+ cells on T cells 
After defining the cell population to study, we performed immunosuppressive function testing by 
co-culturing the selected CD33+ population and T cells (isolated from a single buffy coat). CD33+ 
PBMC isolated from the blood of eight 32-week pregnant women were compared to cells 
extracted from 8 non-pregnant women. The protocol for isolation and access to the donors were 
accepted by the ethical committee of our Institution.  
A slight decrease in proliferation of T cells co-cultured with CD33+ cells from pregnant women 
versus non-pregnant women was observed (Figure 8). These first results were not significant 
possibly due to the large scattering of values, but they were encouraging enough to repeat the 
experiment with 8 new blood samples obtained from unrelated pregnant women. This second 
experiment (Figure 9) confirmed reduced T cell proliferation when co-cultured with CD33+ cell 
from pregnant women compared to non-pregnant women. Moreover, it was associated with a 
CD33+ dose-related decrease in T cell proliferation. 
 
 
 
Figure 8: 3H-Thymidine T cell proliferation assay, first experiment. 
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Figure 9: 3H-Thymidine T cell proliferation assay, second experiment. 
These experiments allowed us also to conclude that there was no significant change in the 
quantity of CD33+ cells circulating in the blood of pregnant compared to non-pregnant women. 
We did not observe the same accumulation which was observed in mice, at least in circulating 
blood. 
 
2.1.3. Immunosuppressive effect of CD33+ cells on NK cells 
The observations of Mauti and her colleagues (1) indicated that murine gestation increases  the 
rate and the degree of tumor dissemination irrespective of the tumor cell origin. Moreover, they 
showed that decreased NK cell numbers and cytotoxicity lead to blunted local clearing of tumor 
cells and demonstrated that MDSC contribute to the reduced NK cell activity and corresponding 
enhancement of tumor dissemination. MDSC isolated from tumor-bearing animals have been 
shown to decrease NK cell activity in a cell contact dependent manner and to be responsible for 
increased tumor dissemination (1). 
To better understand the role of MDSC in human pregnancy and how they function, we 
performed a NK-MDSC co-culture following by a cytotoxicity assay (see material and methods). 
NK cells were isolated from a single buffy coat. They were co-cultured for 18h with CD33+ 
PBMC from blood samples of pregnant and non-pregnant women, activated with human IL-2 
before being plated with target cells (K562 cell line) labeled with 51CrO4. NK cells are known as 
one of the key effectors of tumor cells elimination. K562 tumor cell lysis induced by NK cells 
releases 51CrO4 in the supernatant.  
The result of these co-cultures did not show any direct effect of CD33+ cells extracted from 
pregnant or non-pregnant women on NK cell cytotoxicity (Figure 10). 
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Figure 10: NK-CD33+ co-culture and cytotoxicity assay (mean of 4 32-week pregnant women blood 
samples compared to 4 non-pregnant blood samples). 
 
2.1.4. NK cell ability to target tumor cells 
The CD33 negative fractions of PBMC were used for the assessment of direct cytotoxicity of 
NK cells on K562 cells. The resulting graph was adjusted for NK cell proportions among CD33- 
cells, as determined by flow cytometry. Interestingly, NK cells represented a lower percentage in 
the blood of pregnant than non pregnant women (Figure 11), consistent with the literature. 
However, NK cell cytotoxicity was not significantly different whether the NK cells were 
extracted from the blood of pregnant or non-pregnant women (Figure 12). These observations 
suggest that circulating NK cell activity is not differentially regulated during human pregnancy, 
but NK cells are present in lower quantities. The human CD33+ PBMC population, that bears 
similarity to the mouse MDSC population in terms of the down-regulation of the immune 
response, did not show a direct role in the regulation of NK cell function. 
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Figure 12: NK cell cytotoxicity assay. Mean of 8 32-week pregnant women blood samples compared to 8 
non-pregnant blood samples. 
2.2. Discussion 
Even if we were not able to observe an increased number of CD33+ cells isolated from the 
PBMC layer from pregnant women, we have shown that this population is more 
immunosuppressive during pregnancy compared to non-pregnant state. Physiological changes 
related to human pregnancy may be a permissive precursor state for tumor progression, a 
mechanism that may be linked to reduced immunity mediated by CD33+ cells and by the reduced 
presence of NK cells. Indeed, NK cells have been shown to display reduced cytotoxicity in blood 
isolated from pregnant women. However, our preliminary experiments do not support the 
contribution of CD33+ cells to down-regulation of NK cell activity during pregnancy. 
The main potential difficulties of this study were due to the heterogeneity of the material 
obtained from human origin. Although some characteristics of the blood donors were known 
(20-40 years old women, with no active or chronic diseases and who were 32-weeks pregnant at 
the time of blood sample retrieval), many aspects were not known, including the ethnic origin 
(for the first experiment) and the hormonal status. Furthermore, it may be more difficult to 
strictly identify and isolate MDSC in human compared to mice. 
 
To explore the role of CD33+ cells in pregnancy in more detail and to confirm their similarity to 
myeloid immunosuppressive cells found in tumorigenesis, additional studies are required. Gene 
expression and cytokine production profile studies might help to improve the understanding of 
the role of these cells implicated in tumor progression and pregnancy. Although very preliminary, 
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our results are promising and understanding how CD33+ cells become more immunosuppressive 
during the physiological state of pregnancy and how they recover their resting stage, may lead to 
uncovering ways in which to reverse their activation to restore immunocompetence.  
We know that human cancers are associated with restrained antitumour immunity, driven by 
immunosuppressive cells that participate in resistance to treatment. Thus, the CD33+ 
immunosuppressive cells may represent a therapeutic target whose function can be modulated to 
heighten the efficacy of conventional therapies directed against tumor cells. 
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CONCLUSIONS 
 
The first aim of this work was to assess the MDSC gene expression profile to determine whether 
changes in MDSC features appear prior to tumour implantation and are associated with 
pregnancy itself. The difference between the two states (pregnancy or virginity) was reflected by 
sets of genes found to be differentially expressed between pregnant and virgin mouse MDSC. 
Pregnant mouse MDSC were associated with genes whose products contribute to ECM 
remodeling, tumor progression and the regulation of innate immunity. These genes may 
contribute to the formation of a more permissive and tumor-supportive microenvironment. 
The observations were done in duplicate in two different sets of experiments and selected 
positively modulated genes identified during the array were validated and quantified by qRT-
PCR. This work has several limitations since the number of separate experiments is too low to 
allow optimal quantification and statistical analysis. Furthermore, we focused our interest on 
overexpressed genes and we may well be missing critical genes that are marginally induced during 
pregnancy and/or missing genes that were repressed during pregnancy. Further work will be 
required to evaluate these issues but this is beyond the scope of the current master project. The 
latter was useful to optimize the isolation, enrichment, and RNA preparation from a 
heterogeneous population of cells. Large scale preparation of cells and RNAs was beyond the 
scope of this master project. 
 
The second specific aim of this work was to assess MDSC activity in human pregnancy. The 
isolation of CD33+ cells from peripheral blood obtained from 16 32-week pregnant and 16 non 
pregnant women was successful, and these cells showed a modified function during human 
gestation. MDSC were more immunosuppressive in blood from pregnant women, and NK cells 
showed reduced numbers in blood circulation but their cytotoxic activity needs to be assessed 
with a new batch of samples. The changes in MDSC functions are also found in patients with 
cancer. Others tests will be required to evaluate and confirm this potential dysregulation of 
myeloid cells during human pregnancy. 
 
Cancer-related research tries to improve the understanding of the processes implicated in tumor 
formation and progression with the final purpose to find effective treatments. To restore an 
effective immune system by targeting the MDSC population appears may be a promising 
approach that is worth exploring further.  
Moreover, MDSCs display tumor-associated changes in their gene expression profile that may 
provide targets, contrary to tumor cells that are known to be associated with massive genomic 
alterations and drugs resistance. Thus, research efforts have to be pursued to find judicious 
therapeutic targets within MDSCs that can support and improve conventional therapies directed 
against tumor cells. 
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MATERIALS AND METHODS 
1. In vivo experiments in mice 
1.1. MDSC isolation from mice 
Female C57BL/6 wild-type mice were between 8 and 10 weeks old at the beginning of 
experiments. Experimental procedures involving mice were approved by the Etat de Vaud, 
Service Vétérinaire, authorisation no. VD1477. MDSC were isolated from virgin and 16-day 
pregnant mice splenocytes, as well as from TBM 14-day post-subcutaneous injection of 50 000 
B16-F10 syngenic melanoma cells. Briefly, spleens were extracted from euthanized mice, minced 
through a 100 μm nylon mesh, washed in cold PBS and cells were resuspended in 1mL ACK 
(Ammonium Chloride Potassium buffer) for erythrolysis, 10 minutes at 4°C. After washing in 
MACS buffer (PBS-2 mM EDTA-0.5% BSA), cells were passed through a new 40 μm nylon 
membrane to obtain a single-cell suspension and counted before proceeding to cell isolation 
according to Miltenyi MACS protocol. 
1.2. Magnetic labeling 
After addition to the splenocyte suspensions of FcR Blocking Reagent (blocks unwanted binding 
of antibodies to human Fc receptor-expressing cells, and increases the specificity of antibody 
labeling), the biotinylated anti-Ly-6G antibody was incubated for 10 minutes at 4°C. Cells were 
washed in MACS buffer and the anti-biotin-conjugated magnetic beads were added for a further 
15 minutes incubation period. Samples were washed in MACS buffer, resuspended and separated 
on LS columns placed in the magnetic field of a MACS Separator (Miltenyi Biotec). The positive 
fractions (magnetically retained Ly-6G+ cells) were eluted, and enriched over a second LS column 
to increase the purity of Ly-6G+ cells before being washed and quantified. 
1.3. RNA extraction 
The RNeasy® Mini Kit (Qiagen, Germany) was used for total RNA extraction. RNA purification 
was performed according to the manufacturer’s instructions: cells disruption was obtained using a 
lysis buffer containing β-mercaptoethanol in order to inactivate RNases. The homogenized lysate 
was mixed with 70% ethanol, providing optimal binding conditions, and transferred to a spin 
column to allow total RNA binding to the silica-based membrane of the column. Columns were 
washed three times, and RNA was eluted using 30 μl RNase-free water applied directly to the 
spin column. Quality and quantity of RNA was assessed thanks to a NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies, USA). 
1.4. Flow cytometry analysis of cell phenotypes 
Flow cytometry (FACS for Fluorescence Activated Cell Sorting) is a method for the evaluation of 
cell-membrane proteins and intracellular proteins as well as peptides and DNA. Here we use it 
for the evaluation of cellular markers to identify the result of MDSC isolation through the 
magnetic separation. The principle behind FACS is an antigen-antibody reaction, with the 
antibodies being fluorescently labeled. The suspensions of individual cells pass a focused laser-
beam. Capillary forces cause the cells to pass the flow-cell, where the labels are stimulated by the 
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laser light. The emitted fluorescent light from the fluorophores, which are coupled to the 
antibodies, and the scattered-light are detected separately.1 
The cells scatter a fraction of the light which is then detected by light detectors. The amount of 
light measured correlates with the size of the cells and their complexity. Granulocytes reflect 
more light than smooth surfaced B- or T-cells, due to their rough surface texture and a larger 
amount of vesicles inside the cell. A measurement for the diffraction of light in a flat angle is the 
forward scatter (FSC), which depends on the volume of the cell. A measurement for the 
diffraction of light in a right angle is the so called sidewards scatter (SSC). It depends on the 
granularity, the size of the cells, the structure of its nucleus, and the amount of vesicles inside the 
cells (Figure 13).  
 
Single cell suspensions from spleen were prepared as described above and erythrolysed. Cells 
were counted, 106 cells aliquoted into FACS tubes and washed once with FACS buffer (PBS-
3%FBS-0.9%NaN3). Staining was done in a final volume of 50 μl for 45 minutes at 4°C. 
Antibody dilutions were as follows: CD45-FITC (1:200), CD11b-PE (1:300), Gr1-APC (1:200) 
(all from BioLegend). After washing, cells were fixed in 1% paraformaldehyde in PBS for 10 
minutes at 4°C, washed in FACS buffer and resuspended in the same buffer for an immediate 
acquisition in a FACS Gallios (Beckman Coulter). Kaluza software was used for image analysis 
and quantification of cell populations. 
1.5. Microarray study 
The quality of the total RNA is essential for the overall success of the analysis. The steps of 
fragmentation, hybridization, washing and scanning were performed at the DNA Array Facility 
of Lausanne (DAFL, http://www.unil.ch/dafl). In the present study, the GeneChip Mouse Gene 
1.OST arrays (Affymetrix, UK) were used, representing approximately 29,000 different RNAs, 
                                                          
1
http://www.antibodies-
online.com/resources/17/607/Flow+cytometry+FACS+Principle+and+experimental+setup/ 
Figure 13: Characterization of unstained cells using light scatter (Dot Plot). On the right hand side: large 
cells. On top: ganulary cells. Hence, large granulary cells (eg. Granulocytes) can be found on the top right, 
while small cells which are smooth can be found on the bottom left. 
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which cover almost all genome (Figure 14). Gene expression data normalization and subsequent 
analysis of differentially expressed genes were done by Professor Paolo Provero at the University 
of Turin, using Bioconductor.  
The obtained lists were sorted out according to the estimate of the log2-fold-change of 
expression (log2FC). This value allowed the selection of the most biologically relevant probe sets. 
Genes of interest were selected among the probe sets with log2FC ≥ 1.41, what insured to have 
more than 2-fold-change of expression (log2FC = log2 (Pregnant) - log2 (Virgin)). 
 
Figure 14: Overview of steps needed for Affymetrix microarray hybridization2. 
1.6. Quantitative real-time RT-PCR validation of microarray results 
5 up-regulated genes identified in the microarray study were chosen in order to validate the 
experiment using quantitative real-time reverse transcription-polymerase chain reaction (qReal-
time RT-PCR), that allowed quantitative assessment of gene expression levels. The same quantity 
(500 ng) of total RNA molecules was first transcribed to cDNA in a reverse transcription (RT) 
step.  
                                                          
2
http://compbio.pbworks.com/w/page/16252906/Microarray%20Normalization%20and%20Expression%20Index
#Microarrayrecap 
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The cDNA served as template for the PCR step during which specific region of a gene of interest 
(Table 2) is amplified using gene-specific primers and probes labeled with a fluorescent dye. The 
qReal-time RT-PCR allows the monitoring of the amount of a product by detecting the increase 
of fluorescence intensity released during the PCR reaction. Knowing the amplification efficiency 
of the PCR, which typically is close to a doubling of the number of molecules per amplification 
cycle, it is then possible to evaluate the initial amount of RNA molecules, i.e. the level of 
expression of a particular gene present in a sample. The fluorescence intensity is produced by 
Syber green dye. Syber green intercalates only in the double-stranded DNA (such as PCR 
products obtained during the amplification step) and thus it increases along with the increase of 
the amount of the PCR product. Gene expression was normalized to a housekeeping gene 
(GAPDH). 
Table 2: Primers used for the qRT-PCR  
Fibronectin-1  
Amplicon Size = 87  
Forward AGCCCGGATGTTAGAAGCTA 
Reverse GGCATTGTCGTTCAGAGTGT 
  
Ficolin B  
Amplicon Size = 83  
Forward TGTGACATGGACACAGATGG 
Reverse GTCCAGTCCCGAAAGAAGTC 
  
Inhibin Beta-A  
Amplicon Size = 84  
Forward CTCGGAGATCATCACCTTTG 
Reverse GACAGGTCACTGCCTTCCTT 
  
Chitinase 3-like 3 (Chi3l3)  
Amplicon Size = 95  
Forward TGGTGAAGGAAATGCGTAAA 
Reverse GTCAATGATTCCTGCTCCTG 
  
Olfactomedin 4  
Amplicon Size = 129  
Forward TGCTCGAAGTGGAGATAAGG 
Reverse AGGCCTCACATTCTTTCAGC 
  
GAPDH  
Amplicon Size = 174  
Forward ACCACCAACTGCTTAGCCCCCCTGGCCAA 
Reverse GGATGCAGGGATGATGTTCTGGGCAGCCCCAC 
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2. In vitro experiments with human cells 
We required some preliminary experiments and we used buffy coats in order to develop 
protocols and isolate NK and T cells for the following studies. CD56 MicroBeads were used for 
the positive selection of Natural Killer cells from human PBMC and CD3 MicroBeads for T cell 
isolation (Miltenyi Biotec). 
2.1. Samples 
Whole blood samples were collected from sixteen 32-weeks pregnant and sixteen non-pregnant 
women. Informed consent was obtained and ethical approval for the study was granted by the 
Institutional Ethics Committee. The blood was collected into tubes containing EDTA 
anticoagulant. 
2.2. Isolation of mononuclear cells and granulocytes from human 
peripheral blood by density gradient centrifugation 
Human PBMC and granulocytes were separated from peripheral blood of donors by gradient 
centrifugation on Ficoll-Hypaque (Lymphoprep) at room temperature, according to Miltenyi 
MACS protocol. The blood samples were diluted with 2-4X the volume of buffer (PBS-2 mM 
EDTA) then 20 mL of diluted cell suspension were carefully layered over 6 mL of Ficoll-Paque 
in a 50 mL conical tube. Differential migration during centrifugation (30 minutes, 2000 rpm, 
20°C, without brake) results in the separation of cell types into different layers (Figure 15). The 
bottom layer contains Ficoll-aggregated red blood cells. Immediately above this is a diffuse layer 
containing mostly granulocytes and unbound Ficoll®. Due to a slightly lower density, the 
lymphocytes (including the monocytic PBMC fraction) sediment at the interface between the 
Ficoll® and uppermost plasma/platelet layer.  
PBMC were removed from the interface and subjected to multiple washes in buffer to remove 
any residual Ficoll. The granulocyte layer was therefore collected and resuspended in 8 mL ACK 
for erythrolysis, 10 minutes at 4°C before washing. The cell suspensions were resuspended and 
counted before proceeding to cell isolation according to Miltenyi MACS protocol. 
 
Figure 15: Differential migration following centrifugation results in the formation of several cell layers7. 
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2.3. Magnetic labeling 
The magnetic labeling was performed on the PBMC and granulocyte layers. The method used 
was the same as described above for the mouse side of experiments, but with CD33 or CD11b 
Microbeads, in order to isolate a myeloid cell population. The cell pellets were resuspended in 70 
μL of buffer per 107 total cells and 10 μL of Human FcR Blocking. Then we added 20 μL of 
CD33/CD11b MicroBeads per 107 total cells for 15 minutes incubation at 4°C. Samples were 
washed in MACS buffer, resuspended and separated on LS columns placed in the magnetic field 
of a MACS Separator (Miltenyi Biotec). 
2.4. FACS analysis  
Single cell suspensions were prepared as described above (mice experiments). Antibodies used 
were as follows (1:20 dilution): CD3-PC7, CD11b-APCeFl780, HLA-DR-APC, CD33-eFluor450 
and CD56-ECD. 
2.5. CD33+ cells and T cells co-culture: 3H-Thymidine T cells 
proliferation assay 
To follow the immunosuppressive function of the CD33+ cells, they were co-cultured with T 
cells and plated in a 96-well plate before to add 3H-Thymidine. During each cell division the cell 
will incorporate 3H-Thymidine into its DNA. The more cell divisions (or the higher the 
proliferation rate) the more radioactivity will be incorporated into DNA.  
T cells from one unique buffy coat and CD33+ cells from non-pregnant and pregnant woman 
bloods were mixed in a ratio of 1:1, 1:0.5, 1:2 and 1:4, everything in triplicate, and co-cultured in 
RPMI-1640 plus 10% FBS in a 96-well plate in the presence of anti-CD3/anti-CD28–coated 
beads (Dynal Biotech) at a 1:1 ratio for T cell stimulation. For 3H-thymidine proliferation assays, 
3H-T was added (1 curie/well) after 4 days of co-culture. 18 hours later, the co-culture was 
stopped by frizzing the plate until harvesting cells were washed out of the 96-well plates with 
water and collected on a filter membrane. After drying, the amount of radioactivity was counted 
in a scintillation counter, after adding 25 µL of MicroScint per well. Comparison of the counted 
radioactivity (counts per minute = cpm) of cells allows to evaluate the T cell proliferation in 
presence of different concentrations of immunosuppressive cells. 
2.6. NK-CD33+ co-culture 
MACS-isolated NK cells from one unique human buffy coat and CD33+ extracted from eight 
non-pregnant and eight pregnant women blood samples (one half of the total samples) were 
mixed at 1:1, 1:2, 1:4 ratios (typically 1x104 cells each) and co-cultured for 18h in RPMI-1640-
10%FBS-1%P/S and 500 ng/ml recombinant human IL-2 (in order to activate NK cells) in a 24-
well plate. Cells were collected, counted and aliquoted in triplicates into 96-well plates for 51Cr-
release cytotoxicity assay on the tumor cell line K562 (NK-sensitive human erythromyeloicytic 
leukemia cell line), as described in the following point. 
2.7. 51chromium-release cytotoxicity assay  
We used the negative fraction post-CD33 sorting which should be enriched in NK cells, as 
effectors, maintained overnight at 37°C in complete RPMI + hIL-2 before plating.  
                      
 
30 
 
Single cell suspensions were counted in leukoplate and aliquoted into triplicate wells of conical-
bottom 96-well plates. Starting dilutions were 200:1 and titration was done through serial dilution 
(3:1) into the next 5 wells. As target cells, we used the cell line K562. They were maintained in 
RPMI and split to 3.105 cells/ml 2 days before to testing to ensure that cells are in log phase. On 
the day of testing, cells were washed in PBS and 106 cells were labelled with 51CrO4 for 1h at 
37°C. Labelled cells were washed extensively in complete medium, resuspended in complete 
RPMI, counted and plated with several ratios Effector:Target. After 4h of incubation at 37°C, 
51Cr release into the media was quantified using LumaPlate-96 plates (PerkinElmer) and a Top-
Count-γ-counter (PerkinElmer). 0% lysis was determined with complete medium only, 100% 
lysis by adding 100 μl of 1 M HCl to the target cells. Percentage of lysis was determined by the 
following equation: 100x(sample lysis-0% lysis)/(100%lysis-0%lysis). NK cell proportions of each 
sample were determined by flow cytometry and Effector:Target ratios adjusted accordingly.  
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